metaPreg - Leflunomide during pregnancy

Leflunomide

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.97 [0.81, 1.16]	0%	3 studies	14,378	116	not evaluable	NA
Major congenital malformations	0.97 [0.81, 1.16]	0%	3 studies	14,378	116	not evaluable	NA
4 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Preterm (< 37 weeks)	1.94 [1.03, 3.67]	0%	3 studies	10,871	80	not evaluable	NA
Low birth weight (< 2500g)	1.06 [0.90, 1.25]	0%	2 studies	2	3	not evaluable	NA
2 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Caesarean	-	-	0 study
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
1 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
2 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Early intrauterine death (< 22 weeks)	1.09 [0.90, 1.32]	0%	2 studies	17,747	112	not evaluable	NA
3 non statistically significant endpoints reported in only one study